Skip to main content

AN2 Therapeutics, Inc.

corporate_fare Company Profile

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ANTX - Latest Insights

ANTX
Apr 22, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
ANTX
Apr 20, 2026, 4:33 PM EDT
Filing Type: 424B3
Importance Score:
8
ANTX
Apr 20, 2026, 4:32 PM EDT
Filing Type: 424B5
Importance Score:
8
ANTX
Apr 09, 2026, 5:21 PM EDT
Filing Type: S-3
Importance Score:
9
ANTX
Apr 09, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
8
ANTX
Mar 20, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
8
ANTX
Mar 17, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
8
ANTX
Mar 17, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
ANTX
Mar 09, 2026, 9:43 PM EDT
Filing Type: 8-K
Importance Score:
9
ANTX
Mar 03, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
ANTX
Jan 29, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
7